Cyclin Dependent Kinase 7 - Pipeline Review, H2 2018 - ResearchAndMarkets.com

September 20, 2018

DUBLIN--(BUSINESS WIRE)--Sep 20, 2018--The “Cyclin Dependent Kinase 7 - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC or EC - Cell division protein kinase 7 is an enzyme that in humans is encoded by the CDK7 gene.


The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 7 The report reviews Cyclin Dependent Kinase 7 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in Cyclin Dependent Kinase 7 targeted therapeutics and enlists all their major and minor projects The report assesses Cyclin Dependent Kinase 7 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type The report summarizes all the dormant and discontinued pipeline projects The report reviews latest news and deals related to Cyclin Dependent Kinase 7 targeted therapeutics

Companies Featured

Aurigene Discovery Technologies Ltd. Beta Pharma Inc. Cyclacel Pharmaceuticals Inc. Qurient Co. Ltd. Syros Pharmaceuticals Inc.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/qdb3pm/cyclin_dependent?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180920005370/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs,Enzymes



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/20/2018 07:08 AM/DISC: 09/20/2018 07:08 AM


Update hourly